Clinical Data and Maple Leaf Foods in Agreement to Develop Enhanced Pork Traceability System; Genetic Test to Identify the Source of Any Pork Products Using Novel Genetic Markers.

NEWTON, Mass. -- Clinical Data, Inc. (NASDAQ: CLDA), a worldwide leader in providing comprehensive molecular and pharmacogenomics services as well as genetic tests and clinical diagnostics to improve patient care, announced today that it has entered into an agreement with Maple Leaf Foods Inc. (TSX: MFI), to assist with the further development and commercialization of Maple Leaf's DNA traceability program, a porcine traceability system to genetically trace back any pork product to its farm of origin by means of the Single Nucleotide Polymorphism (SNP)-based (DNA) test. Clinical Data's Cogenics division, a provider of comprehensive pharmacogenomics & molecular services, will conduct the work.

It is anticipated that this technology will be offered to and utilized by other companies in the broader global pork industry. The companies believe that the traceability system will receive wide acceptance by virtue of the compelling food safety and quality benefits that will be realized by producers and consumers.

The DNA traceability system operates through parentage analysis. Blood samples will be collected from every sire and every dam in the farms where traceability is to be established. Each parental animal will have its unique DNA fingerprint recorded in a searchable database. Any porcine product can then be traced back to its farm of origin by DNA tracing to that of a single sire and/or dam. Cogenics will further develop the fingerprinting panel based on a large set of proprietary and highly informative markers spread throughout the porcine genome.

Drew Fromkin, Executive Vice President of Clinical Data, said, "We are truly pleased that Maple Leaf Foods, a leading Canadian food processor, selected us as its partner for commercialization of its pork traceability system, and to act as the genotyping service provider of the system in the Company's next phase of DNA traceability. Clinical Data's Cogenics division, which will be responsible for developing and marketing this system, has industry leading molecular and pharmacogenomics services capabilities and know-how. Our relationship with Maple Leaf is one exciting example of how we can leverage our strong assets in the growing area of food safety and other agricultural applications. This will be the first ever commercial deployment of a large-scale comprehensive system for pork traceability that is both economical and founded on advanced, molecular-genetic principles."

Fromkin added, "The ability to trace a retail food product used for human consumption back to the farm or farms of origin offers tremendous value for producers and consumers. By satisfying the need for rapidly and accurately tracing a food product's place of origin, we believe this traceability system will significantly improve food safety. In effect, Maple Leaf Foods' DNA traceability program is substantially 'raising the bar' for the industry by improving product safety and quality while setting the stage for the industry to provide safer products as a whole. Clearly, the same application of technology has value throughout the porcine products industry in addition to other major agricultural and commodity industries, particularly for products intended for human consumption. We believe Clinical Data and Maple Leaf are building the foundation of a vital technology driven by exciting advances in genomic sciences."

About Maple Leaf Foods Inc.

Maple Leaf Foods Inc. (TSX: MFI) is a leading Canadian food processing company committed to delivering quality food products to consumers around the world. Headquartered in Toronto, Canada, the Company employs approximately 24,000 people at its operations across Canada and in the United States, Europe and Asia. The Company had sales of $6.1 billion in 2005. More information on Maple Leaf Foods can be found at www.mapleleaf.ca.

About Clinical Data, Inc.

Clinical Data, Inc. is a worldwide leader in providing comprehensive molecular and pharmacogenomics services as well as genetic tests to improve patient care. The Company, founded in 1972, is organized under three worldwide divisions segmented by service offerings and varying client constituents: PGxHealth(TM), Cogenics(TM), Vital Diagnostics(TM). Clinical Data's Therapeutic Diagnostics(TM) division, PGxHealth, builds upon existing assets and know-how acquired from Genaissance Pharmaceuticals in the areas of genomics-based, genetic tests and therapeutic efficacy and safety biomarker development for drug utilization. PGxHealth plans to develop and introduce novel Therapeutic Diagnostics in some instances in combination with new and existing therapeutics. Clinical Data's Pharmacogenomics and Molecular Services(TM) division, Cogenics, consolidates the operations of Genaissance Pharmaceuticals, Inc., Lark Technologies, Inc. and Icoria, Inc., each acquired during 2005, and Genome Express SA, acquired in 2006. Cogenics provides a comprehensive range of molecular and pharmacogenomics services to pharmaceutical, biotech, academia, agricultural, and government clients. These services are offered in both research and regulated environments and have applications across the lifecycle of pharmaceutical product development including pharmacovigilance requirements post-launch. Clinical Data's Vital Diagnostics division consolidates the operations of Clinical Data Sales & Service, Inc., Vital Scientific NV, Vital Diagnostics Pty. Ltd., and Electa Lab s.r.l. This division serves the clinical laboratory in the traditional in-vitro diagnostics market worldwide with a focus on the physician's office, hospital and small-to-medium sized laboratory segments. With customers in approximately 100 countries, Vital Diagnostics has achieved a leading market share for instruments and reagents sold into moderately complex physicians' office laboratories within the United States. Clinical Data currently employs a staff of over 430. The Company is headquartered in Newton, Massachusetts with operations in Texas, Connecticut, RTP - North Carolina, Rhode Island, and California as well as internationally in the UK, France, the Netherlands, Italy and Australia. Furthermore, Clinical Data has numerous distribution, licensing, development and other collaborations with key partners.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

This press release contains certain forward-looking information and statements that are intended to be covered by the safe harbor for forward looking statements provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Words such as "expect(s)", "feel(s)", "believe(s)", "will", "may", "anticipate(s)" and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements about our ability to successfully integrate the operations, business, technology and intellectual property obtained in our recent acquisitions; our ability to obtain regulatory approval for, and successfully introduce our new products; our ability to expand our long-term business opportunities; our ability to maintain normal terms with our customers and partners; financial projections and estimates and their underlying assumptions; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, the effects of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include, but are not limited to, whether Clinical Data will be able to develop or acquire additional products and attract new business and strategic partners; competition from pharmaceutical, biotechnology and diagnostics companies; the strength of our intellectual property rights; the effect on the Company's operations and results of significant acquisitions or divestitures made by major competitors; the Company's ability to achieve expected synergies and operating efficiencies in all of its acquisitions, and to successfully integrate its operations; and those risks discussed and identified by Clinical Data in its public filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. Clinical Data does not undertake any obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Readers are also urged to carefully review and consider the various disclosures in Clinical Data's SEC reports, including but not limited to its Annual Report on Form 10-KSB for the fiscal year ended March 31, 2005, and fiscal 2005 and 2006 quarterly reports on Forms 10-QSB and 10-Q.

Internet Website: www.clda.com